Should we buy private Integrated Shield Plans, since Singapore’s subsidised healthcare is world-class?

MoneyOwl’s CEO and Chief Investment Officer, Chuin Ting Weber, shares her perspectives on Integrated Shield Plans.

MoneyOwl
MoneyOwl18 Jun 2024 3728 Views


Note on terminology: A private Integrated Shield Plan (ISP) does not = private hospital coverage.

There are ISPs for B1 and A-class Government wards. Just that the portion that “tops up” MediShield Life is with private insurers.

The recent debate in the news is about the “private private” ISPs – being able to continue with one’s chosen private specialists that fall out of an insurer’s panel. All government specialists are on the panels.

Back to the question.


YES, consider buying an ISP, even if you intend to use B2/C wards, because:

  • MediShield Life has sub-limits to each cost type. These may not catch up to medical inflation quickly enough, and you’ll have to pay more out-of-pocket.
  • That’s why the Government announced recently that they are reviewing MediShield Life.


  • Dialysis. Perhaps not everyone knows this, but you can’t choose subsidised dialysis the same way you choose a subsidised B2/C ward.
  • There is means testing to qualify to use NKF. My late father was a dialysis patient for 3.5 years. Because mum was working, he didn’t qualify. Helpfully, he had an ISP that covered a good part of the $3000/mth bill.

  • Coverage of pre & post-hospitalisation bills, waiting times & choice of doctors
  • IMPORTANT: Even if your company provides insurance, you still need your own ISP. You may not be able to get your own ISP if you have health issues before you leave or retire from your company.


    What’s the strategy for choosing an ISP?

  • Buy the highest coverage you can afford first. Downgrade later if you can’t.
  • But keep all life and health insurance to less than 15% of take-home income (MAS’ Basic Financial Planning Guide).

  • Buy as early as possible, when you DON’T need it.
  • Insurance is one thing on which you don’t want to have a return! Once you have ANY health problems (or even put on weight), you can’t buy or upgrade anymore.

    It’s not wasted: you are insuring your insurability.

  • Don’t go for neither-here-nor-there plans!
  • Recently, there’s a new “starter” type of cheap “private private ISP” that limits claims to $20k/yr. One private surgery can easily bust this. Then you are worse off than if you just got the B-ward plan. It does its job: https://www.moneyowl.com.sg/articles/zhngyour-medishield-life-with-a-low-cost-ip/

  • Do your homework
  • If you are concerned about being upsold (yes, the Shield plan is a door opener for more insurance sales), do some homework yourself, and maybe buy it online.

    MOH has already done a comparison: https://www.moh.gov.sg/healthcare-schemes-subsidies/medishield-life/comparison-of-integrated-shield-plans

    This article was originally published on MoneyOwl's website.


    Shield Plans available on FSMOne:

  • Income - Enhanced IncomeShield
  • Singlife - Singlife Shield
  • Raffles Health Insurance – Raffles Shield

  • Save more when you insure with FSMOne

    Enjoy up to 45% commission rebates when you apply through us


    Reach out to us if you have questions about your hospital coverage, or would like a second opinion on your insurance policies.


    Disclaimer:

    While every reasonable care is taken to ensure the accuracy of information provided, no responsibility can be accepted for any loss or inconvenience caused by any error or omission. The information and opinions expressed herein are made in good faith and are based on sources believed to be reliable but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. Expressions of opinions or estimates should neither be relied upon nor used in any way as indication of the future performance of any financial products, as prices of assets and currencies may go down as well as up and past performance should not be taken as indication of future performance. The author and publisher shall have no liability for any loss or expense whatsoever relating to investment decisions made by the reader.

    This advertisement has not been reviewed by the Monetary Authority of Singapore.





    All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

    Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

    iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.